tetano
Editor, Senior Moderator
Int Immunopharmacol
. 2020 Jun 25;86:106740.
doi: 10.1016/j.intimp.2020.106740. Online ahead of print.
Evaluation of Safety, Efficacy, Tolerability, and Treatment-Related Outcomes of Type I Interferons for Human Coronaviruses (HCoVs) Infection in Clinical Practice: An Updated Critical Systematic Review and Meta-Analysis
Chengjun Yu[SUP] 1 [/SUP], Lian Kang[SUP] 2 [/SUP], Jiadong Chen[SUP] 2 [/SUP], Na Zang[SUP] 3 [/SUP]
Affiliations
Abstract
Background: There is no vaccine or specific antiviral treatment for HCoVs infection. The use of type I interferons for coronavirus is still under great debate in clinical practice.
Materials and methods: A literature search of all relevant studies published on PubMed, Cochrane library, Web of Science database, Science Direct, Wanfang Data, and China National Knowledge Infrastructure (CNKI) until February 2020 was performed.
Results: Of the 1081 identified articles, only 15 studies were included in the final analysis. Comorbidities and delay in diagnosis were significantly associated with case mortality. Type I interferons seem to improve respiratory distress, relieve lung abnormalities, present better saturation, reduce needs for supplemental oxygen support. Type I interferons seem to be well tolerated, and don't increase life threating adverse effects. Data on IFNs in HCoVs are limited, heterogenous and mainly observational.
Conclusions: Current data do not allow making regarding robust commendations for the use of IFNs in HCoVs in general or in specific subtype. But we still recommend type I interferons serving as first-line antivirals in HCoVs infections within local protocols, and interferons may be adopted to the treatments of the SARS-CoV-2 as well. Well-designed large-scale prospective randomized control trials are greatly needed to provide more robust evidence on this topic.
Keywords: Human coronavirus; MERS-CoV; SARS-CoV; SARS-CoV-2; Type I interferons.
. 2020 Jun 25;86:106740.
doi: 10.1016/j.intimp.2020.106740. Online ahead of print.
Evaluation of Safety, Efficacy, Tolerability, and Treatment-Related Outcomes of Type I Interferons for Human Coronaviruses (HCoVs) Infection in Clinical Practice: An Updated Critical Systematic Review and Meta-Analysis
Chengjun Yu[SUP] 1 [/SUP], Lian Kang[SUP] 2 [/SUP], Jiadong Chen[SUP] 2 [/SUP], Na Zang[SUP] 3 [/SUP]
Affiliations
- PMID: 32645630
- DOI: 10.1016/j.intimp.2020.106740
Abstract
Background: There is no vaccine or specific antiviral treatment for HCoVs infection. The use of type I interferons for coronavirus is still under great debate in clinical practice.
Materials and methods: A literature search of all relevant studies published on PubMed, Cochrane library, Web of Science database, Science Direct, Wanfang Data, and China National Knowledge Infrastructure (CNKI) until February 2020 was performed.
Results: Of the 1081 identified articles, only 15 studies were included in the final analysis. Comorbidities and delay in diagnosis were significantly associated with case mortality. Type I interferons seem to improve respiratory distress, relieve lung abnormalities, present better saturation, reduce needs for supplemental oxygen support. Type I interferons seem to be well tolerated, and don't increase life threating adverse effects. Data on IFNs in HCoVs are limited, heterogenous and mainly observational.
Conclusions: Current data do not allow making regarding robust commendations for the use of IFNs in HCoVs in general or in specific subtype. But we still recommend type I interferons serving as first-line antivirals in HCoVs infections within local protocols, and interferons may be adopted to the treatments of the SARS-CoV-2 as well. Well-designed large-scale prospective randomized control trials are greatly needed to provide more robust evidence on this topic.
Keywords: Human coronavirus; MERS-CoV; SARS-CoV; SARS-CoV-2; Type I interferons.